SMOBiO Technology, Inc

NT$30.60As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7422Healthcare

Country Taiwan

PE (Fwd) •••

TSR 10Y CAGR —

Div yield —

ROE —

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap —

ROIC —

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

NT$31

(0.03%)

188.29%

Hold 4|2|11|0|5

TTM

FYE 31 Dec TWD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

80.30

RevenueNT$M

225.0

239.4

257.8

271.8

287.1

305.3

318.1

343.6

367.2

381.1

83.25

5.83%

6.11%

2.71

Revenue growth%

17.53

17.24

14.47

13.37

10.46

12.03

13.54

16.28

16.64

14.24

13.66

14.24

14.35

24.48

Gross margin%

14.67

14.84

13.06

13.86

10.97

9.31

6.69

5.22

3.65

0.90

28.46

5.22

10.14

2.19

Operating margin%

12.28

10.20

10.71

12.70

10.00

11.78

14.30

11.97

13.45

11.96

16.01

11.97

23.69

Net margin%

10.41

12.08

11.03

13.08

13.13

14.84

13.10

15.62

15.34

15.29

10.94

15.29

13.11

17.43

P/E ratio (avg)x

23.07

23.05

22.87

20.37

20.74

22.13

23.59

23.81

22.20

21.78

6.711

22.20

22.54

33.99

EV/EBITx

32.99

29.62

32.04

32.18

32.05

33.68

33.27

32.68

33.20

34.00

37.77

33.27

32.83

5.10

FCF yield (avg)%

31.58

33.47

33.23

35.90

32.95

31.91

29.65

31.58

33.27

32.60

8.38

31.91

32.77

18.72

FCF margin%

1.40

0.40

1.76

1.34

1.29

0.40

1.11

24.21

1.11

0.75

1.026

FCF / Net incomex

0.592

0.545

0.568

0.611

0.636

0.696

0.730

0.640

0.619

0.667

0.271

0.667

0.627

6.05

ROIC%

7.03

7.43

8.07

9.70

8.26

9.54

10.82

11.08

9.72

10.56

19.33

10.56

9.62

17.48

Return on equity%

8.59

10.29

12.94

14.86

16.11

16.66

15.28

16.31

15.34

16.65

19.06

16.31

15.31

4.75

Return on assets%

22.51

24.70

26.78

24.25

22.51

24.84

23.03

25.18

27.98

28.79

10.33

25.18

24.77

3.05

EPSNT$

1.95

2.03

2.20

2.51

2.69

2.93

3.10

3.50

3.34

3.17

4.41%

5.64%

—

14.35

EPS growth%

12.10

11.60

11.41

12.55

12.10

13.34

15.38

17.15

16.66

17.06

4.54

16.66

12.94

0.76

Bookvalue per shNT$

1.41

1.63

1.83

1.71

1.93

2.06

2.32

2.43

2.54

2.94

0.73

8.77%

7.52%

—

1.18

FCF per shareNT$

2.01

1.93

2.11

2.23

1.93

1.67

1.57

1.35

1.28

2.65

(7.98%)

(4.61%)

—

2.56

Dividend per shNT$

1.74

1.59

1.55

1.40

1.32

1.23

1.11

1.14

1.01

0.98

3.08

(5.88%)

(6.13%)

—

13.07

Div yield (avg)%

8.04

5.72

3.34

2.37

3.60

4.07

1.20

0.40

0.43

0.96

6.82

0.96

2.86

11.26

Payout ratio%

24.52

22.84

20.49

21.71

22.85

22.12

22.49

23.10

24.21

23.82

16.60

23.10

22.84

3.770

Shares (diluted)M

3.784

4.130

4.776

5.194

5.079

5.810

7.037

6.962

8.035

9.478

3.763

13.29%

9.84%

3.77

Buyback yield%

17.16

14.66

17.16

16.58

16.42

17.30

17.80

19.19

20.83

21.71

28.75

19.19

17.23

1.652

D/E ratiox

1.684

1.728

1.927

2.049

2.101

2.042

2.356

2.433

2.757

2.701

1.635

2.433

2.075

236.2

Enterprise valueNT$M

279.6

252.3

240.5

258.7

279.3

301.0

305.6

306.2

295.0

264.0

343.2

(1.12%)

(1.65%)

33.62

LT debtNT$M

450.8

514.3

567.2

589.2

615.4

605.9

606.5

634.6

649.0

663.0

428.2

1.50%

5.75%

Peers (US$19.68M)

Cap (US$)

Genomics BioSci…

34.79M

—

FullHope Biomedical…

31.34M

—

Han.biomedical Inc.

17.11M

—

CCME Global Limited

18.76M

—

Capital

TTM

10Y

Leveragex

0.208

0.078

0.076

EBIT/Intx

0.843

1.099

1.073

Own earn%

(64.82)

(75.12)

(50.23)

Sh yield%

16.84

21.26

20.44

Owners

Insiders/Inst%

13.04

68.45

Short interest%

4.71

SBC / revenue%

0.86

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

10–14

$1 testx

−1.2

Incr. ROIC%

SMOBiO Technology, Inc develops and supplies DNA, DNA polymerase, and protein markers. The company offers nucleotide raw materials, pseudouridine-5'-triphosphate, specialized positive lipids, and offers OEM and ODM services. The company was founded in 2004 and is based in Hsinchu City, Taiwan.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

NT$381.1M

6.11%

1.00×

Cost of revenue

NT$195.7M

5.87%

0.98×

Operating expenses

NT$64.20M

6.51%

1.04×